(Reuters) -Drugmaker Pfizer posted a better than expected fourth quarter profit on Thursday, helped by cost cuts and a smaller-than-feared drop in sales of its COVID-19 vaccine. "Our revenue volatility is largely in the past as COVID-related uncertainties have diminished,

Pfizer shares, which had risen Tuesday morning after improved demand for the Covid vaccine, dropped 2.3% after Kennedy's nomination moved forward.

Sales of the Covid vaccine and pill were around $550 million more than analysts had been expecting for the quarter. Pfizer investors are trying to figure out what the “new normal” will be for those products as interest in treating the virus fades with time.

(Reuters) -U.S. drugmaker Pfizer beat Wall Street estimates for fourth-quarter profit on Tuesday, helped by strong sales of its heart disease drug and a smaller-than-feared drop in COVID vaccine sales.